Your session is about to expire
← Back to Search
Vatiquinone for Friedreich Ataxia (MOVE-FA Trial)
MOVE-FA Trial Summary
This trial is testing a drug called vatiquinone to see if it can help improve symptoms of Friedreich ataxia, a rare neurological disorder.
- Friedreich Ataxia
MOVE-FA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMOVE-FA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MOVE-FA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You need to be able to swallow pills.
- Group 1: Placebo
- Group 2: Vatiquinone
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it currently possible to enroll in this clinical trial?
"As of right now, this particular trial has wrapped up recruiting patients. The listing for this trial was first posted on December 17th, 2020 and updated most recently on November 4th, 2022. However, there are still other ongoing trials that may be of interest. Out of the 48 trials currently looking for participants, 4 trials involve Vatiquinone."
Are there a lot of research facilities testing this in Canada right now?
"If you are interested in enrolling in this trial, please note that there are 7 sites recruiting patients. They are situated in Tampa, Los Angeles, Montreal, and 7 other cities. To reduce stress, please try to enroll at the site closest to your location."
Can you give me some other examples of Vatiquinone's usage?
"Vatiquinone was first used in a clinical setting in 2010 at CHOC Children's Clinic. Since that time, there have been a total of 18248 completed clinical trials. At the moment, there are 4 active clinical trials, with a few of these trials based in Tampa, California."
How many patients will be enrolling in this clinical trial?
"This particular trial is not currently admitting patients. However, it was first posted on December 17th, 2020 and was last updated on November 4th, 2022. For individuals who are looking for other studies, there are 48 clinical trials for friedreich ataxia and 4 for Vatiquinone that are currently admitting patients."
Does this clinical trial explore new territory?
"4 clinical trials for Vatiquinone are ongoing in 27 cities and 13 nations. The first study of Vatiquinone was in 2010. PTC Therapeutics sponsored the initial Phase 2 drug approval trial that included 94 patients. Since then, 18248 more trials have concluded."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger